NEW YORK — The US Food and Drug Administration this week granted separate Emergency Use Authorizations for a CRISPR-based SARS-CoV-2 test developed by the University of California, San Francisco and Mammoth Biosciences, and two PCR-based tests from the Broad Institute and BioSewoom.